Association of Centre of Excellence Self-Administered Questionnaire (CESAM) Score and Frailty Levels

April 4, 2024 updated by: Olivier Beauchet, Jewish General Hospital

Association of Centre of Excellence Self-AdMinistered Questionnaire (CESAM) Score and Frailty Levels With Incident Adverse Health Events in Older Community Dwellers: Results of the NuAge Study

This study evaluates the association of the Self-Administered questionnaire (CESAM) score and its stratification of frailty in four levels with incident adverse health events in older community dwellers and to compare this association with three validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index and Rockwood frailty index.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Older adults' health and functional status is heterogeneous because of the various cumulative effects of chronic diseases and physiologic decline, contributing to a vicious cycle of increased frailty. Thanks to advances in medicine and hygiene, a growing number of older adults spend more years with a greater range of disorders causing disability but not mortality. Health systems thus need to face this new challenge. Quantification of frailty and its association with the occurrence of adverse health events is crucial to understand how efficiently health systems may respond to this situation.

This study aims to examine the association of the CESAM score and its stratification of frailty in four levels with incident adverse health events in older community dwellers and to compare this association with a) five validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index, Rockwood frailty index, 6-item brief geriatric assessment (BGA) and "Program of Research on the Integration of Services for the Maintenance of Autonomy" (PRISMA-7) and b) two new frailty indexes developed over the COVID-19 pandemic which are "Évaluation SOcio-GÉriatrique" (ESOGER) and "CriblAge et REcommandations" (CARE).

Study Type

Observational

Enrollment (Estimated)

1741

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Quebec
      • Montréal, Quebec, Canada, H3T 1E2
        • Jewish General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

67 years to 82 years (Older Adult)

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

  • Healthy community-dwellers from Quebec, Canada
  • A follow-up during 4 years

Description

Inclusion Criteria:

-Healthy community-dwellers from Quebec, Canada

Exclusion Criteria:

-Community-dwellers from outside Quebec, Canada

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frailty
Time Frame: the questionnaire will be used once, after 4 years follow-up.
It will be used a questionnaire called:The Centre of Excellence Self-Administered questionnaire(CESAM). This questionnaire evaluates frailty of older adults by providing a score and a stratification of frailty in 4 levels (Vigorous versus mild, moderate and severe frailty).
the questionnaire will be used once, after 4 years follow-up.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jewish General Hospital

Investigators

  • Principal Investigator: Olivier Beauchet, MD, Jewish General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 23, 2019

Primary Completion (Actual)

December 15, 2021

Study Completion (Estimated)

January 1, 2025

Study Registration Dates

First Submitted

May 23, 2019

First Submitted That Met QC Criteria

May 23, 2019

First Posted (Actual)

May 24, 2019

Study Record Updates

Last Update Posted (Actual)

April 5, 2024

Last Update Submitted That Met QC Criteria

April 4, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020-1793

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe